University College London at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

University College London takes part in 3 sessions at CTAD 2026 in Boston. Its program centres on lowering tau with genetic medicines, with early results for an antisense drug and a shuttled siRNA. Its work also covers measuring APOE4 protein in blood to screen for carriers.

Organization	CTAD 2026 Attendance
University College London London, UK
ucl.ac.uk Universities & institutes Its Dementia Research Centre at the Queen Square Institute of Neurology studies inherited and sporadic Alzheimer's, imaging and fluid biomarkers.	Poster Wed Nov 18 7:15am–5:30pm Apolipoprotein E4 quantification by NULISA in cognitively unimpaired cohorts for screening for APOE β4 carriership and homozygosity (P253) Blood and CSF biomarkers Talk Wed Nov 18 8:45am Tau stable isotope labelling kinetics (SILK) and fluid biomarker response to NIO752 – tau MAPT antisense oligonucleotide: an unblinded interim analysis of a phase 1B trial in Alzheimer’s disease Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers Talk Thu Nov 19 1:20pm ARO-MAPT, a Subcutaneously Delivered Shuttled siRNA Silencing Tau Production: Early Phase 1 Safety, Tolerability, and Pharmacodynamic Results in Healthy Volunteers Anti-amyloid and anti-tau therapies

Organization

CTAD 2026 Attendance

University College London

London, UK

ucl.ac.uk

Universities & institutes

Its Dementia Research Centre at the Queen Square Institute of Neurology studies inherited and sporadic Alzheimer's, imaging and fluid biomarkers.

Poster

Wed Nov 18
7:15am–5:30pm

Apolipoprotein E4 quantification by NULISA in cognitively unimpaired cohorts for screening for APOE β4 carriership and homozygosity (P253)

Blood and CSF biomarkers

Talk

Wed Nov 18
8:45am

Tau stable isotope labelling kinetics (SILK) and fluid biomarker response to NIO752 – tau MAPT antisense oligonucleotide: an unblinded interim analysis of a phase 1B trial in Alzheimer’s disease

Anti-amyloid and anti-tau therapies · Blood and CSF biomarkers

Talk

Thu Nov 19
1:20pm

ARO-MAPT, a Subcutaneously Delivered Shuttled siRNA Silencing Tau Production: Early Phase 1 Safety, Tolerability, and Pharmacodynamic Results in Healthy Volunteers

Anti-amyloid and anti-tau therapies

Instantly find 20 buyers from University College London

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction